Claudia Micieli

Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.

C. Brightling, C. Brookes, M. Steiner, 2022, The Lancet. Respiratory medicine.

Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation

I. Pavord, S. Fowler, C. Brightling, 2022, Allergy.